Peerview Internal Medicine Cme/cne/cpe Audio Podcast

Go online to PeerView.com/TGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life. Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising. This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice. Upon completion of this activity, participants should be better able to: Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpr

Go online to PeerView.com/KTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared to safely integrate BCMA-targeting options into the care plan for your relapsed/refractory multiple myeloma (MM) patients, including treatment with antibodies, bispecific agents, and CAR-T cell therapy? Find out in this expert-led MasterClass and Case Forum recorded at the Annual Hematology Meeting. Watch our experts as they offer learners guidance on the “road to remission” in MM, and hear how recent advances with BCMA-targeted therapies can directly lead to enhanced outcomes in the most challenging treatment settings. Throughout, the experts also provide case-based guidance on therapy selection with BCMA antibodies and CAR-T therapy, and illustrate how evidence-based practice can optimize delivery of care in pretreated disease. Get on the “road to remission” for your patients, and receive CME/MOC credit today! Upon completion of this activity, participan

Go online to PeerView.com/FSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of complement-associated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets; Differentially diagnose patients with complement-associated kidney diseases in a timely manner using evidence-based tools and strategies; and Describe current and emerging treatments for complement-associated kidney diseases, including data from recent clinical trials.

Go online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhibitors (TKIs) have demonstrated remarkable efficacy and improved safety in patients with tumors exhibiting RET fusions. However, testing for these fusions and other less common alterations as well as interpreting reports of testing results can be challenging, which can lead to missed opportunities to offer the be

Go online to PeerView.com/YNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Endocrine therapy, typically with an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor, is a mainstay for the management of HR+/HER2- metastatic breast cancer, but many questions still remain about the nuances of optimal use of these and other agents in first- and later-line settings. Furthermore, a number of investigational therapies are showing great promise in HR+/HER2- advanced disease, including novel ER-targeting agents such as oral SERDs, SERMs, SERCAs, PROTACs, and others, as well as antibody–drug conjugates such as those targeting TROP2. It is essential to learn how to best integrate these options into the current treatment arsenal. CDK4/6 inhibition with adjuvant abemaciclib has also changed the standard of care for high-risk patients with earlier-stage disease, but challenges remain, such as determining which patients benefit from this approach, and how to en

Go online to PeerView.com/NMB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current chronic lymphocytic leukemia (CLL) management tool kit is expanding to include covalent and non-covalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies—are you prepared for this challenging and exciting new era in care? This “Seminars & Tumor Board” activity, adapted from our recent live event preceding the 64th ASH Annual Meeting and Exposition, can prepare you to adapt your practice through expert-led, case-based discussion with mini seminars designed to illustrate how fully integrating cutting-edge treatments can improve care in different and often challenging treatment settings. This program also features important resources from our collaborative partner, the CLL Society, that can be used to engage with your CLL patients during disease management. Upon completion of this activity, participants should be better able to: C

Go online to PeerView.com/ENP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Did you miss the PeerView DLBCL Seminar & Tumor Board at the Annual Hematology Meeting in New Orleans or want to revisit this important educational event? Access this program to watch a panel of experts debate the emergence of potent, antibody-based treatment platforms for patients with DLBCL, including novel CD19-directed antibodies, antibody-drug conjugates, and CD3xCD20 bispecific agents. These discussions are paired with case scenarios offering guidance on how to integrate these platforms into personalized management for DLBCL patients. The panel also explores the identification of candidates for treatment with novel antibodies; therapeutic sequencing and bridging strategies; and appropriate safety management and monitoring. Don’t miss this informative video to receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize upda

Go online to PeerView.com/DNP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your skills in managing tenosynovial giant cell tumors (TGCT)—particularly in light of updated phase 3 evidence supporting systemic treatment? Find out in this final part of an educational series on TGCT, where an expert in the field reviews current standards of care and provides updates from a major clinical trial that supports the use of targeted options in conjunction with established multimodal treatment protocols for TGCT management. Upon completion of this activity, participants should be better able to: Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients where continued surgery is unlikely to produce clinical benefits; and Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemi

Go online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investigations are underway in earlier disease settings and in various rational combinations. How can you make the most of these new ADC options in the context of other available therapies, and what is the best way to integrate them into practice? This activity, based on a PeerView Live MasterClass & Practicum educational symposium, addresses these and many other critical questions. By combining insightful analyses of the most recent data with compelling discussions of cases and practicalities, our international expert panel he

Go online to PeerView.com/YGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding therapeutic landscape for prostate cancer has provided new opportunities for oncology and urology professionals to improve outcomes through individualized patient care. With new and emerging strategies in both the hormone-sensitive and -resistant settings, treatment of patients with prostate cancer requires knowledge of next-generation anti-androgen agents, PARP inhibitors, and use of immunotherapy, radioligands, and other strategies alone or in active combinations, along with guidelines for testing and treatment. In this activity, urologic oncology experts pair in-depth analysis of efficacy and safety evidence with a case-focused discussion of best practices for bringing treatment advances to the clinic. Featured topics include novel therapeutic approaches, strategies for collaboration with other clinicians and patients to optimize care, and the role of clinical t

Go online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, a panel of leading bladder cancer experts pairs important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity wil

Go online to PeerView.com/SFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) have had a strikingly positive impact on the treatment of a range of cancer types by blocking intrinsic downregulators of the immune response to increase antitumor immunity. A number of ICIs and ICI-based combinations have been approved for use in many solid and liquid malignancies, and intense research efforts promise to expand their role in advanced cancers and early-stage, curative-intent settings. While immunotherapy has become a pillar of cancer treatment and is considered safe, ICIs are associated with a spectrum of unique toxicities termed immune-related adverse events (irAEs). These irAEs can affect any organ system in the body, including the heart and cardiovascular system, occur at any point during or after treatment, and vary in presentation from mild to severe, and sometimes life threatening. Cardiac pathology attributed to irAEs i

Go online to PeerView.com/UHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), as well as appropriate strategies to differentiate cold agglutinin disease from other forms of AIHA in providing optimal care for patients. Upon completion of this activity, participants should be better able to: Recognize the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), and Employ appropriate strategies to differentiate cold agglutinin disease (CAD) from other forms of autoimmune hemolytic anemia (AIHA) to provide optimal care for patients.

Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging th

Go online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improve patient outcomes. Designed to guide professionals into a new era of team-based personalized care, this Seminars & Tumor Board activity features a multidisciplinary panel of experts who will link current science and treatment recommendations to practical guidance on therapeutic decision-making. Using case-based discussion, the expert panel will address a variety of clinical issues such as treatment selection, sequencing, and the integration of systemic therapy with locoregional management. It takes a team to provide t

Go online to PeerView.com/TSR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an expert panel examines the latest evidence for currently approved targeted agents in systemic lupus erythematosus (SLE) and lupus nephritis (LN) and offers personal anecdotes and reflections to illustrate how scientific findings can inform everyday clinical practices and guide individualized approaches to care. Additionally, the panel discusses the need for culturally competent care to ameliorate healthcare disparities offering evidence-based tools and tactics to overcome barriers and improve access to care and health information needs for patients in marginalized populations. Upon completion of this activity, participants should be better able to: Employ best practices related to the diagnosis and assessment of SLE and LN; Describe the pathophysiology of SLE and LN, recognizing targets for therapeutic intervention; Outline t

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify,

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify,